Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001026263 | SCV001188608 | pathogenic | Hereditary cancer-predisposing syndrome | 2019-01-14 | criteria provided, single submitter | clinical testing | The c.7313_7314dupCA pathogenic mutation, located in coding exon 49 of the ATM gene, results from a duplication of CA at nucleotide position 7313, causing a translational frameshift with a predicted alternate stop codon (p.V2439Qfs*2). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV001382900 | SCV001581859 | pathogenic | Ataxia-telangiectasia syndrome | 2020-07-07 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant has not been reported in the literature in individuals with ATM-related conditions. ClinVar contains an entry for this variant (Variation ID: 826959). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Val2439Glnfs*2) in the ATM gene. It is expected to result in an absent or disrupted protein product. |